California’s ACA exchange will punish hospitals ordering unnecessary procedures

Covered California, the state’s Affordable Care Act marketplace, has announced a new initiative aimed at cracking down on common problem areas for hospitals by staking their in-network status on meeting safety and quality goals.

As California Healthline reports, hospitals will be expected to perform fewer unnecessary C-sections, cut down on imaging procedures for lower back pain and prescribe fewer opioids. If they don’t do so by the end of 2019, Covered California will try to get participating health insurers to exclude those hospitals from their networks.

C-sections in particular have been a major source of unnecessary care ordered by hospitals based on costs rather than patients’ needs. California Healthline said the C-sections take less time (40 minutes for a scheduled procedure versus 24-hour on-call staffing for vaginal deliveries) while allowing the hospital to charge more. Even for low-risk deliveries, several California hospitals are delivering 40 percent of babies by C-section, according to Covered California’s chief medical officer Lance Lang, MD.

“That means that when a woman goes to a hospital, it’s the culture of the hospital that really determines whether or not she gets a cesarean section, not so much her own health,” Lang said.

Covered California is setting a much lower C-section rate of 23.9 percent for hospitals to keep their in-network status.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.